Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...
TikTok is a rapidly growing social media platform on which users develop, interact with, or share short vertical videos ...
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts ...
Genmab A/S today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's ...
A central theme of Sinch’s Q2 presentation was the company’s focus on AI integration across its product portfolio. CEO Laurinda Pang emphasized that "AI is fundamentally transforming how businesses ...
Despite remarkable success in relapsed or refractory B-cell malignancies, CAR T-cell therapy faces significant challenges: primary resistance, relapse, and treatment-related toxicities. This talk ...
Alfa Sigma presented its Q2 2025 earnings results on July 24, highlighting the completion of its corporate transformation into a pure-play packaged food business. The company reported strong EBITDA ...
The presentation revealed that Alfa shares began trading as a dedicated food business on April 7, following the spin-off of Alfa’s share ownership in Alpek on October 24, 2024, with shareholders ...
Colonial SFL presented its first half 2025 results on July 24, 2025, highlighting strong financial performance driven by rental growth in prime central business district (CBD) locations. The company’s ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PowerCell Sweden AB ( (SE:PCELL)) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback